Journal article
A Review of Immunotherapy in Non-Small-Cell Lung Cancer
Current oncology (Toronto), Vol.31(6), pp.3495-3512
06/01/2024
DOI: 10.3390/curroncol31060258
PMCID: PMC11203112
PMID: 38920741
Abstract
Cancer immunotherapy in the form of immune checkpoint inhibitors has led to a dramatic increase in the survival of patients with lung cancer across all stages. Over the past decade, the field has experienced rapid maturation; however, several challenges continue to complicate patient management. This review aims to highlight the data that led to this dramatic shift in practice as well as to focus on key challenges. These include determining the optimal therapy duration, managing frail patients or those with brain metastases, addressing the challenges posed by immune-related adverse events, and defining the various patterns of clinical and radiological responses to immunotherapy.
Details
- Title: Subtitle
- A Review of Immunotherapy in Non-Small-Cell Lung Cancer
- Creators
- Mariana Pilon Capella - Jewish General HospitalSteph A. Pang - Jewish General HospitalMarcos A. Magalhaes - Beneficência Portuguesa de São PauloKhashayar Esfahani - St Mary's Hospital
- Resource Type
- Journal article
- Publication Details
- Current oncology (Toronto), Vol.31(6), pp.3495-3512
- DOI
- 10.3390/curroncol31060258
- PMID
- 38920741
- PMCID
- PMC11203112
- NLM abbreviation
- Curr Oncol
- ISSN
- 1198-0052
- eISSN
- 1718-7729
- Publisher
- MDPI
- Number of pages
- 18
- Language
- English
- Date published
- 06/01/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984946628202771
Metrics
5 Record Views